CBMR researcher receives a grant from the Federation of European Biochemical Society

Om Rathore, CBMR researcher, received a grant from the Federation of European Biochemical Society with the project Use of iCLIP to define the in vivo RNA binding sites of Salsa.

The project involves a stay at the Institute of Molecular Biology, in Mainz, Germany, and aims to understand the splicing regulation in Drosophila (fruit fly).

Assuming that 95% of human genes are alternatively spliced and 50% of rare genetic disorders are cause by errors in the splicing process, the researchers believe that Drosophila could help them to uncover the function of splicing process in different diseases.

The research will help to understand how the disease develops and could lead to develop new biomarkers, diagnostic approaches and therapies.


CBMR researchers are at the Famelab 2018 semi-final

Catarina Raposo and João Santos, CBMR researchers, advanced, yesterday, to the final round of Famelab 2018 – the most famous international science communication competition.

With presentations on cancer and heart problems, the students stood out from the remaining candidates guaranteeing a place in the next tie, to be held on 18th March at Pavilhão do Conhecimento, in Lisbon.

Catarina Raposo spoke about “The superpowers of cancer”, being the most voted by the public, and João Santos presented the communication “Heart, the motor of the human body”, surprising the jury with a performance in which established an approximation between the functioning of the human heart system and a car engine.

The competition is organized by Ciência Viva – National Agency for Scientific and Technological Culture and by the British Council, in partnership with universities and centers of science and technology throughout the country, and aims to promote the practice of science communication.

Each competitor has three minutes to demonstrate his ability to communicate the most diverse scientific subjects, using only the word and the gesture and without the aid of audiovisuals.


CBMR hosts school students to showcase the research developed at the centre

Last thursday CBMR opened the labs and received school students to showcase the research developed in areas such as cancer, diabetes, neurodegenerative diseases, turbeculosis, etc.

The research centre developed five activities to captivate students for the research area: “DNA extraction”, “Chicken Embryo Development”, “Problem Based Learning Case”, “Use of Droshopila  for Biomedical Research” and “Study the wonderful world of our brain”.



CBMR researcher tests innovative therapy for biotechnology company in France

Clévio Nóbrega, CBMR researcher, has recently established a partnership with BrainVectis, a biotechnology company based in Paris, to test a genetically based therapy for neurodegenerative diseases.

The Molecular Neuroscience and Therapy Lab will, over the next six months, carry out, in cellular models, additional tests about the mechanism of action of the therapy.

If the tests are successful, the company, whose main objective is to stop the progression of neurodegenerative diseases, will continue to focus on the investigation of Clévio Nóbrega (who was, in 2017, distinguished with the Award of Young Scientist of the Year), moving towards experiments on animal models.

Know more about the research here.


Rui Martinho is the new Vice-President of Portuguese Society for Developmental Biology

Rui Martinho, CBMR researcher and Principal Investigator of  “The Drosophila Development Laboratory”, was recently elected Vice-President of the Portuguese Society for Developmental Biology (SPBD).

The SPBD is a nonprofit organization that aims to represent and strengthen the interactions among developmental biologists working in Portugal.

It was created in 2006 and launched with pomp and circumstance in a successful meeting at the Instituto Gulbenkian de Ciência. Read here what the first SPBD president, Isabel Palmeirim, has to say about the first steps of the SPBD and read the enthusiastic meeting report published in the International Journal of Developmental Biology.

Congratulations, Rui!


CBMR project highlighted on TV

CBMR – Centre for Biomedical Research was featured in RTP3 through the MicroBioWines Project, a research project led by Margaret Soares, CBMR researcher. The project results from a consortium between Herdade da Malhadinha, University of the Algarve and Biocant and aims to explore the way how microbiology can help to produce more natural wines.



CBMR researchers may help to treat more aggressive brain tumors

Patrícia Madureira and her team published in the latest issue of Cells Magazine a scientific article that may help to understand gliobastoma multiforme, one of the deadliest brain tumors.

Assuming that low tumor oxygenation, also known as hypoxia, constitutes a major concern for gliobastoma multiforme patients, since it promotes cancer cell spreading (invasion) into the healthy brain tissue in order to evade this adverse microenvironment, the research team seeks to understand how this contributes to tumor cells becoming more invasive.

In a cancer whose patient prognosis is quite reserved, with a patient’s median survival rate ranging from 15 to 17 months, the goal is clear: to help develop, in the future, more effective therapies for this type of tumor.

Since tumor invasion is the leading cause of death in patients with gliobastoma multiforme and also the main obstacle to treatment, researchers seek to understand how hypoxia triggers the GBM cells to become invasive is paramount to developing novel and more effective therapies against this devastating disease.

With this work, researchers from the CBMR – Center for Research in Biomedicine  (University of the Algarve) and the Brain Tumor Research Center (University of Portsmouth, U.K), concluded that there are several cellular proteins involved in promoting invasion in this type of brain tumors and that they should be pointed out as potential therapeutic targets for the treatment of the disease. Some chemotherapeutic agents are already being tested in clinical trials.

The current treatment for gliobastoma multiforme involves tumor resection surgery based on MRI image analysis, followed by radiotherapy and treatment with temozolomide. However, the gradual development of tumor resistance to temozolomide is frequent in GBM patients leading to subsequent tumor regrowth/relapse.

The treatment for gliobastoma multiforme has not changed since 2005, so, this study may open a new opportunity window.


CBMR researcher awarded by the Portuguese Society of Human Genetics

Ana Fernandes, CBMR researcher of the Functional Genomics of Cancer Group, led by Ana Teresa-Maia, won recently the “Prize for Basic Research”, a prize attributed by the Portuguese Society of Human Genetics to the better work in the area of human genetics.

The prize aims to distinguish the talk “miRNA-mediated cis-regulation in breast cancer susceptibility”, presented on 17th November at the 21st Annual Meeting of the Portuguese Society of Human Genetics.

In the talk the researcher addressed the contribution of the cis-regulation in breast cancer susceptibility.

According to the researcher, “receiving this award is not only an acknowledgment of the work done during the last year but also of the quality of research carried out in the CBMR.”


CBMR researchers discovered new biomarker for cancer detection

Scientists have discovered that there is a gene that is involved in the process of development and progression of the disease and that can help in the diagnosis and prognosis of pancreatic cancer, one of the most difficult to detect.

Inês Faleiro and a group of researchers from CBMR, led by Pedro Castelo-Branco, have published in Future Oncology a scientific article that focuses on the discovery of a new biomarker that allows to detect pancreatic cancer earlier.

The research, carried out by the Epigenetics and Human Disease group, found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples.

However, the potential of the discovery of this new biomarker goes beyond the diagnosis possibilities since, being measurable in terms of percentage, the analysis of THOR methylation levels offers researchers important prognostic data to understand, in each patient, what the stage of evolution of the disease and, even, its degree of aggressiveness.

This finding reveals that patients with elevated levels of THOR methylation have lower survival rates and patients with low levels of THOR methylation appear to have better treatment prospects.

It should be noted that, since pancreatic cancer is one of the cancers that presents the highest mortality rate due to a late diagnosis, this finding may, in a long term basis, contribute to a faster detection of the disease, making it more effective in terms of treatment.


More information: